<DOC>
	<DOCNO>NCT02217007</DOCNO>
	<brief_summary>This open-label study SNC-102 ( acamprosate calcium sustain release tablet ) adult subject Tourette Syndrome . Subjects treat oral dos SNC-102 800 mg BID basis - breakfast bedtime - 4 week subject treat SNC-102 1600mg morning 800mg even additional 4 week . Subjects assess change tic severity , safety , pharmacokinetics . The study hypothesis treatment SNC-102 improve tic severity adult subject Tourette Syndrome .</brief_summary>
	<brief_title>A Trial Evaluating Efficacy , Safety , Pharmacokinetics SNC-102 Subjects With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Diagnosis Boardcertified neurologist psychiatrist Tourette Syndrome accord Diagnostic Statistical Manual ( DSM ) V criteria Tourette 's Disorder , viz . Both multiple motor one vocal tic present time illness , although necessarily concurrently . The tic may wax wane frequency persist 1 year since first tic onset . Onset age 18 year . The disturbance attributable physiological effect substance ( e.g. , cocaine ) another medical condition ( e.g. , Huntington 's disease , postviral encephalitis ) . Moderate severe tic indicate Clinical Global Impression ( CGI ) score 4 high Screening Visit Baseline Visit usual drug therapy Tourette Syndrome . If use permit medication ( SSRI , Serotoninnorepinephrine reuptake inhibitor ( SNRI ) , alpha2 agonist , benzodiazepine , dopamine antagonist , stimulant ) dose stable least 4 week prior Screening Visit expect remain stable conclusion study . Ability swallow investigational tablet whole without chew , demonstrate swallow placebo tablet Screening Visit . Diagnosis epilepsy . Treatment antiepileptic drug exception stable dose clonazepam . Topiramate lamotrigine specifically exclude . Unstable psychiatric status , indicate change psychotropic medication ( unless approve Sponsor ) , psychiatric hospitalization , within 30 day prior Screening Visit . Active drug alcohol dependence abuse . Current use cocaine , amphetamine , phencyclidine , ketamine , document either history urinary drug screen Screening Baseline Visits . Drugs use treat attention deficithyperactivity disorder obsessivecompulsive symptom allow stable least 4 week prior Screening Visit expect remain stable course trial . Any drug identify drug screen warrant exclusion Principal Investigator , consultation Sponsor , judge presence could interfere objective trial . Risk significant medication nonadherence , base judgment Principal Investigator . History neuroleptic malignant syndrome . Significant risk , judgment Principal Investigator , suicidal violent behavior . Female subject history premenstrual exacerbation tic . Initiation oral contraceptive medication , insertion progestin contraceptive implant , change dose , within 30 day prior Screening Visit , anticipate participate trial . History shortbowel malabsorption syndrome , gastrointestinal hypermotility cause , gastrointestinal disease surgery , judgment Principal Investigator , could interfere absorption orallyadministered medication , reduce intestinal transit time predispose gastric outlet obstruction . Allergy intolerance acamprosate . Prior treatment acamprosate indication . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . Use investigational agent within 4 week Baseline . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tourette</keyword>
	<keyword>Tourette 's</keyword>
	<keyword>tic</keyword>
</DOC>